SCHEMBL215877

SCHEMBL215877

CN1CCCc2cc(N)ccc2C1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 11/20 0.55
DRD5 P21918 10/20 0.55
DRD2 P14416 8/20 0.47
DRD4 P21917 8/20 0.47
DRD3 P35462 8/20 0.47
MAOA P21397 2/20 0.46
MAOB P27338 2/20 0.46
BRD4 O60885 1/20 0.43
ATAD2 Q6PL18 1/20 0.43
HSD17B3 P37058 1/20 0.43
NR1H2 P55055 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951275 0.95 DRD1 (0.49) DRD1DRD5DRD2DRD4DRD3
SCHEMBL218317 0.89 MAOA (0.59) DRD1DRD5DRD2DRD4DRD3
SCHEMBL30561544 0.89 MAOA (0.59) DRD1DRD5DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL4521948 0.87 MAOA (0.60) DRD1DRD5DRD2DRD4DRD3
SCHEMBL188753 0.83 MAOA (0.55) DRD1DRD5DRD2DRD4DRD3
SCHEMBL29506615 0.83 MAOA (0.55) DRD1DRD5DRD2DRD4DRD3
SCHEMBL216418 0.83 DRD1 (0.51) DRD1DRD5DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL4513459 0.81 MAOA (0.57) DRD1DRD5DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL3773192 0.81 DRD1 (0.50) DRD1DRD5DRD2DRD4DRD3
Hydrochloric Acid SCHEMBL4591079 0.81 DRD1 (0.50) DRD1DRD5DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2016-06-09 US disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 DRD1 2845/4885DRD5 1428/4885DRD2 1670/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK DRD1 3360/4885DRD5 4098/4885DRD2 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.